Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001093557-21-000231)

Filing Details

Accession Number:
0001093557-21-000231
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-16 19:01:53
Reporting Period:
2021-09-15
Accepted Time:
2021-09-16 19:01:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1093557 Dexcom Inc DXCM Surgical & Medical Instruments & Apparatus (3841) 330857544
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1286858 R Kevin Sayer 6340 Sequence Drive
San Diego CA 92121		 Chairman, Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-09-15 400 $536.49 102,305 No 4 S Direct
Common Stock Disposition 2021-09-15 1,050 $537.45 101,255 No 4 S Direct
Common Stock Disposition 2021-09-15 413 $538.63 100,842 No 4 S Direct
Common Stock Disposition 2021-09-15 700 $539.59 100,142 No 4 S Direct
Common Stock Disposition 2021-09-15 640 $540.92 99,502 No 4 S Direct
Common Stock Disposition 2021-09-15 1,252 $541.88 98,250 No 4 S Direct
Common Stock Disposition 2021-09-15 932 $543.18 97,318 No 4 S Direct
Common Stock Disposition 2021-09-15 613 $544.07 96,705 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. On July 31, 2020, Mr. Sayer adopted a 10b5-1 Plan, which was amended effective June 15, 2021. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.
  2. This transaction was executed in multiple trades at prices ranging from $536.13 to $536.92. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. Included in this number are 36,385 unvested restricted stock units, 13,445 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 16,968 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 5,972 of which were granted on March 8, 2019 and shall vest through March 8, 2022.
  4. This transaction was executed in multiple trades at prices ranging from $537.13 to $537.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  5. This transaction was executed in multiple trades at prices ranging from $538.20 to $539.16. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  6. This transaction was executed in multiple trades at prices ranging from $539.310 to $540.135. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  7. This transaction was executed in multiple trades at prices ranging from $540.44 to $541.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  8. This transaction was executed in multiple trades at prices ranging from $541.48 to $542.44. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  9. This transaction was executed in multiple trades at prices ranging from $542.69 to $543.66. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  10. This transaction was executed in multiple trades at prices ranging from $543.74 to $544.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.